A Center for Computational Imaging and Personalized Diagnostics (CCIPD) technology licensed by a startup has received FDA approval and is in the IBM AI marketplace. The vascuCAP software analyzes CT angiograms to characterize plaque tissues in a manner that could previously only be done with a tissue specimen. This software will now be more accessible to healthcare providers on IBM’s Imaging AI Marketplace.
Read more on Business Wire here.
